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Letters e111Lesions of TTS most commonly occur in the
second trigeminal division dermatome, followed by
the first and third.2 One case of TTS involving all
3 branches of the trigeminal nerve in the context
of surgical resection for meningioma has been
reported.3 Another report described a patient in
whom trigeminal sensory dysfunction developed 1
year after meningioma excision and subsequently
ala nasi ulceration developed 6 weeks after a third
surgery.4
Trigeminal dysfunction causing facial numbness
was reported in 11% of patients who underwent
surgery for cranial base meningiomas.5 Nerve
injury was attributed in some patients to intra-
operative dissection within the cavernous sinus,
tumor infiltration, or gross injury to the nerve
distal to the cavernous sinus; 42% of patients had
no identifiable cause. We report a case of TTS
involving V1-V3 related to a recurrent meningi-
oma. Although our patient had a history of surgical
resection and Gamma-Knife therapy, which could
have caused trigeminal nerve damage, the associ-
ation with additional neurologic symptoms and
the evidence visualized on neuroradiologic imag-
ing suggest recurrent disease as the etiology of the
TTS. Interestingly, the appearance of skin lesions
preceded the development of headaches, suggest-
ing that TTS can indicate neurologic disease
before the development of other neurologic
symptoms.
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Open access under CC BY-NC-ND license.Striking leflunomide efficacy against
refractory cutaneous sarcoidosis
To the Editor: Sarcoidosis, a multisystemic granulo-
matous disease of unknown etiology, involves the
skin in about 25% of cases.1 We describe leflunomide
efficacy in 2 patients whose cutaneous sarcoidoses
were refractory to conventional therapies.
Patient 1 was a 46-year-old woman with lung
(stage 1), skin, and nasosinusal sarcoidosis lasting
16 years. Her medical history included hypertension
and thalidomide-induced lower limb neuropathy.
Skin lesions were resistant to topical steroids,
tacrolimus, hydroxychloroquine, thalidomide, and
methotrexate; the patient refused oral prednisone.
Leflunomide (20 mg/day) was started alone because
she had progressive nasosinusal involvement and
cutaneous lesions on her limbs and buttocks, and a
large patch on her right cheek (Fig 1, A).
Angiotensin-converting enzyme (ACE) level was
84 (normal \41 IU/mL). Dramatic cutaneous
improvement was noted at 6 months, and complete
remission (CR) of cutaneous (Fig 1, B) and
nasosinusal lesions was obtained after 1 year of
leflunomide therapy as shown by normal ACE level
and normal control skin biopsy of the left arm.
Because sarcoid joint manifestations occurred
whenever the leflunomide dose was decreased to
less than 10 mg/day, maintenance therapy with that
dose was pursued without any relapse after 34
months. Vulvar and cervical intraepithelial neopla-
sias, diagnosed after 24 months, were treated with
surgical excision and cervical conization, respec-
tively, without recurrence 1 year later.
Patient 2, a 51-year-old woman with type 1
diabetes and hypertension had stage 1 lung and
nasosinusal sarcoidosis and severe facial lupus
pernio (Fig 2, A) lasting 9 years that was resistant to
topical and systemic corticosteroids, thalidomide,
infliximab, etanercept, efalizumab, methotrexate
alone, methotrexate combined with hydroxychlor-
oquine, and intralesional corticosteroid injections.
Leflunomide (20 mg/day) was added to a stable
methotrexate dose (20 mg/wk). Striking regression
of skin lesions and nasosinusal symptoms was
obtained after 4 months of leflunomide therapy
(Fig 2, B). Discontinuing methotrexate and
Fig 1. A, Sarcoidosis skin lesions on the right cheek in patient 1 before leflunomide treatment.
B, Complete remission in patient 1 after 12 months of leflunomide treatment.
Fig 2. A, Severe facial lupus pernio in patient 2 before combined leflunomide and
methotrexate treatment. B, Rapid partial response of the facial lupus pernio in patient 2 after
4 months of combined leflunomide and methotrexate treatment.
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and nasosinusal relapses. Reintroducing metho-
trexate (15 mg/week) reestablished partial remission
(PR). No adverse events occurred.
After failure of topical steroids and antimalarials,
oral corticosteroids remain the major treatment
for cutaneous sarcoidosis.2 In the case of steroid
resistance or intolerance, methotrexate and tumor
necrosis factor-alphaeblocking agents have the
highest levels of evidence justifying their use.2
Leflunomide, an immunomodulatory drug-
inhibiting dihydroorotate dehydrogenase, a mito-
chondrial enzyme involved in pyrimidine synthesis,
prevents the expansion of activated T lymphocytes,
which are key actors in sarcoidosis pathogenesis. In
2003, Majithia and colleagues reported the first case
of leflunomide efficacy in a patient with sinusal and
facial sarcoidosis with sinusal CR and skin PR.3 Since
then, leflunomide efficacy alone or combined with
methotrexate against sarcoidosis skin lesions has
been investigated in 18 patients in 2 retrospective
studies focusing on refractory cases of pulmonarysarcoidosis.4,5 Leflunomide skin response was
described in 13 patients (12 with CR or PR), but
detailed follow-up and digital photos were lacking.
Leflunomide side effects include infections, periph-
eral neuropathy, liver dysfunction, and interstitial
lung disease. To our knowledge, in situ squamous
cell carcinomas have never been associated with
leflunomide use. Our data show clear evidence of
leflunomide long-term efficacy in patients with skin
sarcoidosis that is difficult to treat. However, large
prospective studies are needed to confirm these
observations.
Geroˆme Bohelay, MD,a Jean-David Bouaziz,
MD, PhD,b,c Hilario Nunes, MD, PhD,d,e Michel
Rybojad, MD,b Martine Bagot, MD, PhD,b,c
Antoine Petit, MD,b and Liliane Laroche,
MD, PhDa,e
Hoˆpital Avicenne, Assistance Publique-Hoˆpitaux
de Paris (AP-HP), Service de Dermatologie,
Bobigny,a Hoˆpital Saint-Louis, AP-HP, Service
de Dermatologie, Paris,b Universite Paris
Fig 1. Bullous fixed drug eruption: Erythematous circular
superficial erosion with desquamative scale overlying left
nasal ala.
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Localized bullous fixed drug eruption
following yellow fever vaccine
To the Editor: Yellow fever is a potentially fatal,
mosquito-borne disease endemic to areas of South
America and Africa. The yellow fever vaccine is
recommended to those traveling to high-risk areas
and is considered one of the safest and most effective
vaccines ever developed. The vaccine is a live atten-
uated version of the 17D strain grown in egg embryos
and imparts durable immunity for 10 years. Reported
dermatologic side effects of the vaccine include mild
injection site reactions, urticaria, and anaphylaxis.1
We report a case of an injection site reaction
followed by a localized bullous fixed drug eruption
after the administration of the yellow fever vaccine.
Hours after receiving the vaccine, a painful edematous
plaque developed at the injection site in a healthy 56-
year-old woman. Four days later, she reported devel-
opment of large, asymptomatic bullae localized to her
nose. The lesions increased in size and eventually
ruptured with minimal crust. She presented to our
clinic 10 days after receiving the vaccine. The patient
had no known allergies to medications, eggs, or
vaccines, and denied a history of herpes or changes
to her medication regimen. She reported no insect
bites, trauma, or burns to the area. On exam, therewasa 1.2-cm erythematous, circular, superficial erosion
with desquamative scale overlying the left nasal ala
with scant hemorrhagic and serous crust (Fig 1).
Superficial erosions were also appreciated on the
columella. An erythematous patch surrounded the
injection site on the upper right arm. Biopsy, culture,
and direct immunofluorescence were deferred given
thebenign exam.Because the lesionswerehealing, no
specific treatment was indicated. The eruption cleared
2 days later without scarring or dyspigmentation.
The history and clinical findings were consistent
with the yellow fever vaccine producing a mild
injection site reaction and subsequent bullous fixed
drug eruption on the left nasal ala. Herpes simplex,
herpes zoster, and arthropod bites, while considered
with findings of bullae, were unlikely here given the
history, time course, and lack of symptoms. The
possibility of bullous impetigo was also weighed but
the characteristic turbid vesicular fluid and yellow
crusting were not present and the patient did not
possess risk factors such as sick contacts. Autoimmune
blistering diseases were not favored due to the
localized and self-limited nature of the lesions.
Although rare, various bullous eruptions have
been described following vaccination. Bullous pem-
phigoid has been reported to occur most commonly
after receipt of the influenza vaccine, as well as after
receipt of the diphtheria-tetanus-pertussis vaccine.2
Influenza and human papillomavirus vaccinations
have triggered the appearance of linear IgA bullous
disease.3,4 Generalized bullous fixed drug eruption
has developed after receipt of the flu vaccine.5
Unlike our patient’s limited and self-resolved erup-
tion, these eruptions were widespread, generally
requiring systemic therapy and an autoimmune
